Enzo Biochem (ENZ)
This company is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. This stock closed up 7.7% to $2.78 in recent trading.
Today's Range: $2.56-$2.81
52-Week Range: $1.33-$3.12Volume: 291,000 Three-Month Average Volume: 164,030 Shares of ENZ soared higher today after the company said its Enzo Clinical Labs has introduced a new diagnostic test that assist in risk assessment and early detection of lung cancer. It is being made available to physicians in the New York metropolitan market as well as New Jersey and Eastern Pennsylvania, where Enzo is the only clinical laboratory making the test available within those areas. From a technical perspective, ENZ bounced higher today right around some near-term support at $2.47 with above-average volume. This stock has been trending sideways for the last month, with shares moving between $2.40 on the downside and $3.09 on the upside. Shares of ENZ are now pushing within range of triggering a major breakout trade. That trade will hit once ENZ manages to take out some near-term overhead resistance levels at $2.80 to $3.09 and then once it clears some past overhead resistance at $3.12 with high volume. Traders should now look for long-biased trades in ENZ as long as it's trending above $2.47, and then once it sustains a move or close above those breakout levels with volume that hits near or above 164,030 shares. If that breakout triggers soon, then ENZ will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.88. Keep in mind that any move above $3.12 would send ENZ into new 52-week high territory, which is bullish technical price action. To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV